2023 World Conference on Lung Cancer (Posters)-EP13.07. Understanding Real-Life Response to Lurbinectedin as Second Line Therapy in Patients with Extensive Stage Small-Cell Lung Cancer

EP13.07. Understanding Real-Life Response to Lurbinectedin as Second Line Therapy in Patients with Extensive Stage Small-Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

The presentation discussed the real-life response to lurbinectedin as a second-line therapy in patients with extensive-stage small-cell lung cancer (ES-SCLC). Lurbinectedin is a recently approved treatment for ES-SCLC. The study aimed to evaluate the efficacy and tolerance of the drug in a real-world setting.<br /><br />The researchers conducted a retrospective chart review of 29 patients who received lurbinectedin at the University of Michigan Rogel Cancer Center between August 2020 and January 2023. The patients had a median age of 65 years and had previously received an average of two treatments. The median progression-free survival (PFS) and overall survival (OS) of the patients were 3.0 months and 5.6 months, respectively. <br /><br />The study found a 31% incidence of serious adverse events, including pneumonia, febrile neutropenia, and tumor lysis syndrome. The patients in the real-world setting had different clinical characteristics compared to those enrolled in the phase II trial that led to FDA approval. These differences included the presence of brain metastases and prior treatment with immune checkpoint inhibitors (ICI). <br /><br />The findings of the study suggested that the benefits of lurbinectedin in a real-world setting may be less robust than reported in the clinical trial. The researchers highlighted the need for effective therapies for ES-SCLC and emphasized the importance of considering patient characteristics, such as prior ICI treatment, presence of brain metastases, and performance status, in determining treatment outcomes. <br /><br />Overall, the study underscored the importance of evaluating the real-life efficacy and tolerability of drugs like lurbinectedin to guide treatment decisions and improve outcomes for patients with ES-SCLC.

Asset Subtitle

Katherine Curt

Meta Tag

Speaker Katherine Curt

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

lurbinectedin

extensive-stage small-cell lung cancer

second-line therapy

real-life response

efficacy

tolerance

retrospective chart review

progression-free survival

overall survival

adverse events